COMPUTEX
31.5.2021 08:31:06 CEST | Business Wire | Press release
COMPUTEX kicked off this year’s month-long #COMPUTEXVirtual on May 31 with James Huang, TAITRA Chairman, highlighting the not-to-be-missed events. Michelle Johnston Holthaus, Intel Executive Vice President, Chief Revenue Officer, discussed accelerating digital transformation and how to release a new era of innovation when the world is most looking forward to innovation. On the same day, Arm CEO Simon Segars discussed the role of technology in the post-pandemic. Using examples from Arm's ecosystem partners, Segars demonstrated how technology could be a remarkable force for good that will be critical to the world’s recovery and create a more sustainable and secure future. Breaking away from traditions, COMPUTEX 2021 Virtual is an all-virtual exhibition, using AI platforms and leading the way to create a prosperous technology ecosystem.
“COMPUTEX was born in the 1980s when the technology industry took off. At that time, together with entrepreneurs from around the world, Taiwan pursued disruptive innovation and created an industry supply chain that paved the way for the Internet and digital economy that we have today. It has been one year into the pandemic, and we continue to push forward with innovation and navigate in the new normal. As Taiwan stands at the center of the global technology ecosystem, we will never cease to build, connect, integrate, innovate, and push forward with the latest technologies. Today, I am honored to announce the opening of #COMPUTEXVirtual. No matter where we are, let COMPUTEX connect us for a better future,” said James Huang, TAITRA Chairman.
COMPUTEX 2021 Opening Keynote by Intel is led by Executive Vice President and Chief Revenue Officer Michelle Johnston Holthaus with the theme of "Innovation Unleashed". Intel talks about sustainability awareness of enterprises under the raging global pandemic and how we continue to work with global partners to promote digital transformation; Intel not only response to the global market demand quickly and flexibly with the IDM 2.0 business model, but it also continues to promote innovation with 5G and its Open Architecture. We will also unveil new products leading in performance and enrich people’s user experience.
Arm CEO Simon Segars’ keynote titled “Sparking the World’s Post-Pandemic Recovery” demonstrated how technology can be a remarkable force for good that will be critical to the world’s recovery and create a more sustainable and secure future. The combination of computing in the age of AI will accelerate how we tackle complex challenges surrounding climate change, security, and equitable access to technologies and connectivity. Segars indicated that long-term investments in research and development are the key to shaping that future. Arm has invested significant resources in its next-generation architecture. Armv9 will enable partners to solve hard problems in the next decade of compute related to security, compute efficiency, and AI-enabled services, all while fighting climate change at the same time.
A Variety of Events for an All-New Virtual Experience
COMPUTEX 2021 Virtual offers live demonstration of the latest solutions on 5G, AI & IoT, Edge Computing, High-Performance Computing (HPC), Gaming, and Innovations and Startups.
The month-long online exhibition also includes a variety of events, including the #COMPUTEXVirtual online exhibition, COMPUTEX CEO Keynote, COMPUTEX Keynote, COMPUTEX & InnoVEX Forum, and COMPUTEX Matchmaking, giving attendees direct access to the leading tech manufacturers and the latest technology trends. The exhibition also enables the exhibitors to effectively seize business opportunities through the online matchmaking platform.
The #COMPUTEXVirtual online exhibition features Tech Insights, Virtual Displays, Matchmaking and Networking, and Hyper-Personalized Recommendations. #InnoVEXVirtual, the exclusive exhibit for startups, offers vibrant synergy on the other hand. #COMPUTEXVirtual is now open until June 30 midnight. Register now for free at: https://virtual.computextaipei.com.tw/
For more updates:
COMPUTEX website: https://www.computextaipei.com.tw/
InnoVEX website : https://www.innovex.com.tw/
About COMPUTEX TAIPEI (also called COMPUTEX):
Established in 1981, COMPUTEX is one of the leading global ICT, IoT, and startup tradeshows with a complete supply chain and IoT ecosystems. Co-organized by the Taiwan External Trade Development Council (TAITRA) and Taipei Computer Association (TCA), COMPUTEX, based upon Taiwan’s complete ICT clusters, covers the whole spectrum of the ICT industry, from established brands to startups and from ICT supply chain to IoT ecosystems. With strong R&D and manufacturing capabilities and IPR protection, Taiwan is a strategic destination for foreign companies and investors looking for partners in global technology ecosystems. Follow COMPUTEX on its website at www.computextaipei.com.tw and Twitter @computex_taipei using the hashtag #COMPUTEX.
About COMPUTEX 2021 Virtual:
As a pioneer in technology, COMPUTEX has been at the forefront in embracing digital transformation. In 2021, the show will go online. Together with the key global technology players, the organizer of COMPUTEX, Taiwan External Trade Development Council (TAITRA) introduces #COMPUTEXVirtual (including its global startups and innovations showcase #InnoVEXVirtual), an AI-driven virtual platform, and aims to deliver an exceptional virtual exhibition experience beyond the distance.
About TAITRA:
Founded in 1970, TAITRA is Taiwan's foremost nonprofit trade promoting organization. Sponsored by the government and industry organizations, TAITRA assists enterprises to expand their global reach. Headquartered in Taipei, TAITRA has a team of 1,300 specialists and operates 5 local offices in Taoyuan, Hsinchu, Taichung, Tainan and Kaohsiung, as well as 63 branches worldwide. Together with Taipei World Trade Center (TWTC) and Taiwan Trade Center (TTC), TAITRA has formed a global network dedicated to promoting world trade.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210530005044/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom